Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NVNO enVVeno Medical Corp
- Stocks
- Healthcare
- NASDAQ: NVNO
Price (delayed)
$3.63
Market cap
$63.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$61.7M
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product
Highlights
The EPS has grown by 29% year-on-year and by 7% since the previous quarter
NVNO's debt is down by 26% YoY and by 8% from the previous quarter
NVNO's quick ratio is down by 19% YoY but it is up by 14% QoQ
The equity has declined by 10% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of NVNO
Market
Valuations
Earnings
Shares outstanding
17.54M
Market cap
$63.66M
Enterprise value
$61.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$23.28M
Net income
-$21.33M
EBIT
-$21.33M
EBITDA
-$20.82M
Free cash flow
-$17.33M
Per share
Balance sheet
Liquidity
EPS
-$1.18
EPS diluted
-$1.18
Free cash flow per share
-$0.85
Book value per share
$2.18
Revenue per share
$0
TBVPS
$1.99
Total assets
$40.58M
Total liabilities
$2.27M
Debt
$979,000
Equity
$38.31M
Working capital
$37.82M
Debt to equity
0.03
Current ratio
23.77
Quick ratio
23.44
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.2%
Return on equity
-51.3%
Return on invested capital
-57.4%
Return on capital employed
-54.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVNO stock price
How has the enVVeno Medical stock price performed over time
Intraday
-3.71%
1 week
9.67%
1 month
71.23%
1 year
-28.82%
YTD
20.2%
QTD
38.02%
Financial performance
How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.28M
Net income
-$21.33M
Gross margin
N/A
Net margin
N/A
enVVeno Medical's net income has increased by 3.6% YoY and by 2.2% from the previous quarter
enVVeno Medical's operating income has increased by 2.8% YoY and by 2.3% QoQ
Price vs fundamentals
How does NVNO's price correlate with its fundamentals
Growth
What is enVVeno Medical's growth rate over time
Valuation
What is enVVeno Medical stock price valuation
P/E
N/A
P/B
1.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 29% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 39% lower than the 5-year quarterly average of 2.7 but 28% higher than the last 4 quarters average of 1.3
The equity has declined by 10% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is enVVeno Medical business performance
NVNO's ROE is up by 18% year-on-year
The company's return on assets rose by 16% YoY
The ROIC has grown by 11% YoY
Dividends
What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVNO.
Financial health
How did enVVeno Medical financials performed over time
The company's total liabilities fell by 19% QoQ and by 8% YoY
NVNO's quick ratio is down by 19% YoY but it is up by 14% QoQ
NVNO's debt is 97% less than its equity
NVNO's debt is down by 26% YoY and by 8% from the previous quarter
The equity has declined by 10% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.